Skip to search formSkip to main contentSkip to account menu

Antrin brand of motexafin lutetium

Known as: Antrin 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Sequelae of atherosclerotic vascular disease (for example, acute myocardial infarction or stroke) are leading causes of death… 
2006
2006
The aim of this study was to evaluate the effect of superovulation treatment using combination of CIDR, FSH and hCG in beef… 
Highly Cited
2003
Highly Cited
2003
Background—Motexafin lutetium (MLu; Antrin) is a photosensitizer that is taken up by atherosclerotic plaque and concentrated… 
Review
2002
Review
2002
Photodynamic therapy (PDT) has been approved as a tissue‐specific light‐activated cytotoxic therapy for many diseases. The… 
2001
2001
  • P. Yeung
  • IDrugs : the investigational drugs journal
  • 2001
  • Corpus ID: 26246734
Pharmacyclics is developing the photosensitizer, motexafin lutetium as Antrin for the potential treatment of restenosis and… 
1998
1998
  • D. Miles
  • Photonics West - Biomedical Optics
  • 1998
  • Corpus ID: 73241963
ANTRINTM photosensitizer, a lutetium texaphyrin-containing drug, is currently being evaluated in the clinic as a phototherapeutic… 
Review
1990
Review
1990
1989
1989
The three widely distributed peptides derived from prosomatostatin are the original neurohormone somatostatin-14, somatostatin-28…